To help determine whether the p16INK/p19ARF pathway, which is commonly affected in cancers [23], is downregulated in tumors mediated by Nek1 deficiency or inactivation, we examined p19ARF in NEK1 -/- cells. Here, CDKN2A is linked to cancer.